Physician profile
Nancy E Amoroso
NPI 1740449917
$2,356.97
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,020 · 2020: $436 · 2021: $633 · 2022: $143 · 2023: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $473.30 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $471.81 | 2020-2022 | |
| Melinta Therapeutics, LLC | $425.68 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.00 | 2019-2023 | |
| Pfizer INC. | $184.56 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $171.67 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $169.06 | 2019-2022 | |
| Chiesi USA, INC. | $75.97 | 2019 | |
| Abbott Laboratories | $64.48 | 2022 | |
| Vapotherm INC | $26.31 | 2019 | |
| Csl Behring | $24.04 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.09 | 2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Amoroso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.